Nirmatrelvir-ritonavir use among adults hospitalized with COVID-19 during the Omicron phase of the COVID-19 pandemic, Canadian Nosocomial Infection Surveillance Program
Background: Recent studies have demonstrated the effectiveness of nirmatrelvir-ritonavir in reducing the risk of progression to severe disease among outpatients with mild to moderate coronavirus disease 2019 (COVID-19); however, data are limited regarding the use and role of nirmatrelvir-ritonavir among hospitalized patients. This study describes the use and outcomes of nirmatrelvir-ritonavir among adults hospitalized with COVID-19 in a sentinel network of Canadian acute care hospitals during the Omicron variant phase of the pandemic.
Methods: The Canadian Nosocomial Infection Surveillance Program conducts surveillance of hospitalized patients with COVID-19 in acute care hospitals across Canada. Demographic, clinical, treatment and 30-day outcome data were collected by chart review by trained infection control professionals using standardized questionnaires.
Results: From January 1 to December 31, 2022, 13% (n=490/3,731) of adult patients (18 years of age and older) hospitalized with COVID-19 in 40 acute care hospitals received nirmatrelvir-ritonavir either at admission or during hospitalization. Most inpatients who received nirmatrelvir-ritonavir, 79% of whom were fully vaccinated, had at least one pre-existing comorbidity (97%) and were of advanced age (median=79 years). Few were admitted to an intensive care unit (2.3%) and among the 490 nirmatrelvir-ritonavir treated inpatients, there were 13 (2.7%) deaths attributable to COVID-19.
Conclusion: These findings from a large sentinel network of Canadian acute-care hospitals suggest that nirmatrelvir-ritonavir is being used to treat adult COVID-19 patients at admission who are at risk of progression to severe disease or those who acquired COVID-19 in hospital. Additional research on the efficacy and indications for nirmatrelvir-ritonavir use in hospitalized patients is warranted to inform future policies and guidelines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Canada communicable disease report = Releve des maladies transmissibles au Canada - 49(2023), 7-8 vom: 01. Aug., Seite 351-357 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mitchell, Robyn [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 09.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.14745/ccdr.v49i78a07 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36945619X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36945619X | ||
| 003 | DE-627 | ||
| 005 | 20240309232554.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240308s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14745/ccdr.v49i78a07 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1321.xml |
| 035 | |a (DE-627)NLM36945619X | ||
| 035 | |a (NLM)38455882 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mitchell, Robyn |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nirmatrelvir-ritonavir use among adults hospitalized with COVID-19 during the Omicron phase of the COVID-19 pandemic, Canadian Nosocomial Infection Surveillance Program |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 09.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Background: Recent studies have demonstrated the effectiveness of nirmatrelvir-ritonavir in reducing the risk of progression to severe disease among outpatients with mild to moderate coronavirus disease 2019 (COVID-19); however, data are limited regarding the use and role of nirmatrelvir-ritonavir among hospitalized patients. This study describes the use and outcomes of nirmatrelvir-ritonavir among adults hospitalized with COVID-19 in a sentinel network of Canadian acute care hospitals during the Omicron variant phase of the pandemic | ||
| 520 | |a Methods: The Canadian Nosocomial Infection Surveillance Program conducts surveillance of hospitalized patients with COVID-19 in acute care hospitals across Canada. Demographic, clinical, treatment and 30-day outcome data were collected by chart review by trained infection control professionals using standardized questionnaires | ||
| 520 | |a Results: From January 1 to December 31, 2022, 13% (n=490/3,731) of adult patients (18 years of age and older) hospitalized with COVID-19 in 40 acute care hospitals received nirmatrelvir-ritonavir either at admission or during hospitalization. Most inpatients who received nirmatrelvir-ritonavir, 79% of whom were fully vaccinated, had at least one pre-existing comorbidity (97%) and were of advanced age (median=79 years). Few were admitted to an intensive care unit (2.3%) and among the 490 nirmatrelvir-ritonavir treated inpatients, there were 13 (2.7%) deaths attributable to COVID-19 | ||
| 520 | |a Conclusion: These findings from a large sentinel network of Canadian acute-care hospitals suggest that nirmatrelvir-ritonavir is being used to treat adult COVID-19 patients at admission who are at risk of progression to severe disease or those who acquired COVID-19 in hospital. Additional research on the efficacy and indications for nirmatrelvir-ritonavir use in hospitalized patients is warranted to inform future policies and guidelines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a hospitalized patients | |
| 650 | 4 | |a nirmatrelvir-ritonavir | |
| 700 | 1 | |a Lee, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a Pelude, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Comeau, Jeannette |e verfasserin |4 aut | |
| 700 | 1 | |a Conly, John |e verfasserin |4 aut | |
| 700 | 1 | |a Ellis, Chelsey |e verfasserin |4 aut | |
| 700 | 1 | |a Ellison, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Embil, John |e verfasserin |4 aut | |
| 700 | 1 | |a Evans, Gerald |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Lynn |e verfasserin |4 aut | |
| 700 | 1 | |a Johnstone, Jennie |e verfasserin |4 aut | |
| 700 | 1 | |a Katz, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Kibsey, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Bonita |e verfasserin |4 aut | |
| 700 | 1 | |a Lefebvre, Marie-Astrid |e verfasserin |4 aut | |
| 700 | 1 | |a Longtin, Yves |e verfasserin |4 aut | |
| 700 | 1 | |a McGeer, Allison |e verfasserin |4 aut | |
| 700 | 1 | |a Mertz, Dominik |e verfasserin |4 aut | |
| 700 | 1 | |a Minion, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Srigley, Jocelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Suh, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Tomlinson, Jen |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Thampi, Nisha |e verfasserin |4 aut | |
| 700 | 1 | |a Frenette, Charles |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Canada communicable disease report = Releve des maladies transmissibles au Canada |d 1994 |g 49(2023), 7-8 vom: 01. Aug., Seite 351-357 |w (DE-627)NLM012649449 |x 1188-4169 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2023 |g number:7-8 |g day:01 |g month:08 |g pages:351-357 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14745/ccdr.v49i78a07 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2023 |e 7-8 |b 01 |c 08 |h 351-357 | ||